Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease

Catheterization and Cardiovascular Interventions

Volumn 71, Issue 7, 2008, Pages 886-893

  Ramana, Ravi K ^a   Ronan, Adam ^a   Cohoon, Kevin ^b   Homan, David ^b   Sutherland, Jessica ^a   Steen, Lowell ^a   Liu, Jayson ^c   Loeb, Henry ^c   Lewis, Bruce E ^a,d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c Mental Health Service Line   (United States)

^d NONE   (United States)

Author keywords

Drug eluting stent; Saphenous vein graft; Sirolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN; WARFARIN; CARDIOVASCULAR AGENT; METAL;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; SAPHENOUS VEIN GRAFT; VEIN GRAFT DISEASE; AGED; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; FEASIBILITY STUDY; FOLLOW UP; GRAFT OCCLUSION; INSTRUMENTATION; KAPLAN MEIER METHOD; PATIENT SELECTION; PROSTHESIS; REGISTER; RESTENOSIS; RISK ASSESSMENT; SAPHENOUS VEIN; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSPLANTATION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; MALE; METALS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SAPHENOUS VEIN; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 45849138540     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21552     Document Type: Article

References (29)

1. Kaiser C, Brunner-La Rocca HP, Buser FT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366:921-929.
2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
4. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-1115.
5. Schofer J. Schluter M. Gcrshlick AH. et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
6. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP. Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-1061.
7. Camenzind E. Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern. Circulation 2007;115:1440-1455; discussion 1455.
8. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
9. Lagerqvist B. James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
10. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006; 27:2784-2814.
11. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591.
12. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007;370:937-948.
13. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402.
14. James SK. SCAAR update: DES compared to BMS in Sweden. Annual TCT Meeting. Washington, D.C., 2007.
15. Jensen L.DES registry: DES compared to BMS in Western Denmark. Annual TCT Conference. Washington, D.C., 2007.
16. Chu WW, Kuchulakanti PK, Wang B, et al. Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention. J Interv Cardiol 2006;19:121-125.
17. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005;45:989-994.
18. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J Am Coll Cardiol 2006;48:2423-2431.
19. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 2007;50:261-267.
20. Moore P, Taney BM, Hermiller JB. Off label use of drug-eluting stents: No advantage in saphenous vein grafts. Annual TCT Meeting. Washington, D.C., 2007.
21. Hoffmann R, Hamm C, Nienaber C, et al. Implantation of sirolimus-eluting stents in saphenous vein grafts. Annual TCT Meeting. Washington, D.C., 2007.
22. Bairn DS. Percutaneous treatment of saphenous vein graft disease: The ongoing challenge. J Am Coll Cardiol 2003;42:1370-1372.
23. Ellis SG, Kandzari D, Kereiakes DJ, et al. Utility of sirolimus-eluting cyphertrade mark stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: Results of a multicenter 350-patient case-control study. J Invasive Cardiol 2007;19:404-409.
24. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
25. Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337:740-747.
26. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005;66:512-513.
27. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97:34-37.
28. Mayor S. Drug eluting stents are safe for licensed indications. FDA panel says. BMJ 2006;333:1235.
29. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med 2007;356:325-328.